SYDNEY, Australia, June 8 /PRNewswire-FirstCall/ -- Ritract (ASX: RTL - News) Limited today reported US Food & Drug Administration (FDA) clearance to begin marketing its range of auto-retractable safety syringes in the USA. Ritract Managing Director, Rupert Northcott, said Ritract would soon begin a sales test program with B. Braun (Melsungen) AG. The test will include the full range of Ritract auto-retractable safety syringes (1ml, 3ml, 5ml and 10ml) before an anticipated wider international sales and distribution agreement.
